yfimuna.wordpress.com
After reaching a 52-week high of $7.5 3 per share on Aprikl 16, the company's shares are now tradiny at around $4.19 a share on the Nasdaq. The Dubli n company has $86.6 millioj in cash and no debt at the end of its secons quarterthis year. Its leading candidate, a drug that knock s out the proteins that help canced cells growand spread, could move into a Phase 1b trial later this year, Manuso That's a significant step closed to FDA approval.
Four other drugs developed withthe company's fast computeer modeling system are in line for later Dacogen, a treatment for leukemia-linke bone marrow disease the company licensezs to , could earn the company $21 million in royalty payments, said American Technology Research, a Connecticut analyst firm, initiatedd coverage of SuperGen Sept. 5 with a rating, saying those payments supporgt a higher valuation forthe company's which it thinks could reach $8 per In the last year, the stock has range d between $3.92 to $7.53. Manusol made a presentation at Healthcare Conferencwe inBoston Sept. 4.
He'lp present at Bear Stearns Healthcare Conference in New York Cityon 11, ThinkEquity Partners' Fifth Annual Growth Conference in San Francisco latefr this month, and at A.G. Edwards ' Second Annual Emerging Growth Conference in New YorkCity 18. Some of the othed East Bay biotech executives on the conference tracthis month: CFO David Smith will present at ThinkEquity. CEO Roberrt Johnson, CEO Joerg Reinhardt, and CEO Mark McDade will present at Bear Representativesof , , and PDL's McDaded will present at the Thinok Equity. Representatives of and will presenat A.G. Edwards.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment